Cernitol Novum is now available in France under the brand name Cernitol 47 mg.

Cernelle is expanding internationally by entering a large and promising market. The French have great confidence and long history of using herbal pharmaceuticals. Cernitol is the first drug approved using pollen extract, as a the active pharmaceutical ingredient, to effectively treat symptoms caused by benign prostate hyperplasia (BPH).

It is estimated that 2 million men in France suffer from benign prostate diseases. Prevalence data shows that one out of two men between 55 and 70 years and eight out of ten men in their 80s have symptoms that are connected with benign prostate hyperplasia (BPH).

French men who want to befriend their prostate, have now a new effective alternative with Cernitol 47mg.

About AB Cernelle: Cernelle is a Swedish pharmaceutical company with research and development of medicine in urology; chronic prostatitis/pelvic pain syndrome (CP/CPPS) and benign prostate hyperplasia (BPH). Cernelle has developed herbal pharmaceuticals from pure pollen extract since 1953. With over 50 million daily doses per year, Cernilton®/Cernitol® is one of the world's most used medicine to treat benign prostate diseases.

The company have 40 employees, located at the facilities outside Ängelholm in Southern Sweden. Cernelle is owned by Backahill AB since 2005.